摘要
采用免疫组化法检测MT1在40例骨肉瘤及20例骨软骨瘤组织中的表达。结果显示MT1在骨肉瘤中的表达率(70%)明显高于骨软骨瘤(35%)(P<0.05)。MT1的表达与骨肉瘤的Enneking分期、复发和转移相关(P<0.05),而与性别、年龄、肿瘤体积、Dahlin's组织学分型无关(P>0.05)。因此,MT1可作为骨肉瘤术后风险判断指标之一;同时为褪黑素提供了结合靶点,为研究外源性褪黑素在治疗骨肉瘤中的应用提供了依据。
Immunohistochemical method was used to detect the expression of MT1 in 40 cases of osteosareoma and 20 cases of osteochondroma tissues. There was a significant overexpression of MTI in osteosarcoma tissues as compared with osteochondroma tissues. The difference was significant （P〈0.05）. Furthermore, the expression of MT1 in osteosarcoma tissues was correlated with Enneking＇s Staging ,recurrence and metastasis （P〈0.05） , but not with gender,age,tumor volume and Dahlin＇s differentiation （P〉0.05） . MT1 may become a useful marker for evaluating prognosis of osteosarcoma patients. These findings may have implications for the use of melatonin in osteosarcoma therapy.
出处
《医学与哲学（B）》
2011年第5期57-58,68,共3页
Medicine & Philosophy(B)
关键词
褪黑素受体
骨肉瘤
免疫组织化学
melatonin receptor,osteoarcoma,immunohistochemistry
